Identification | Back Directory | [Name]
Benzamide, N-(4-chlorophenyl)-4-(1H-tetrazol-5-yl)- | [CAS]
651769-78-7 | [Synonyms]
Xanthine oxidoreductase-IN-3 N-(4-Chlorophenyl)-4-(1H-tetrazol-5-yl)benzamide Benzamide, N-(4-chlorophenyl)-4-(1H-tetrazol-5-yl)- | [Molecular Formula]
C14H10ClN5O | [MOL File]
651769-78-7.mol | [Molecular Weight]
299.715 |
Hazard Information | Back Directory | [Uses]
Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia[1]. | [in vivo]
Xanthine oxidoreductase-IN-3 (compound IIIa) (5 mg/kg; p.o.) shows a uric acid-lowering effect from 3 h after administration in mice with acute hyperuricemia[1]. Animal Model: | ICR mice (18-22 g) were induced acute hyperuricemia by injection of potassium oxonate and hypoxanthine[1] | Dosage: | 5 mg/kg | Administration: | Suspended in 0.5% CMC-Na solution for intragastric administration | Result: | Showed a uric acid-lowering effect from 3 h after administration. |
| [References]
[1] Peng W, et, al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947. DOI:10.1016/j.ejmech.2022.114947 |
|
Company Name: |
nanjing
|
Tel: |
13376082704 13376082704 |
Website: |
www.linye-e.com/ |
|